GlassScriptPhysician profile
Manasa Vulchi
NPI 1760739296
$4,790.70
in general payments reported to CMS, 2019-2025
46 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $287 · 2020: $1,234 · 2021: $1,831 · 2022: $1,090 · 2023: $146 · 2024: $64.31 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304 · Education: $45.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $303.78 |
| Education | $45.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,048.11 | 2019-2022 | |
| Glaxosmithkline, LLC. | $349.11 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $308.69 | 2020-2022 | |
| Eisai INC. | $256.55 | 2019-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $227.33 | 2021-2022 | |
| Amgen INC. | $208.55 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $204.99 | 2020-2022 | |
| Seagen INC. | $202.85 | 2019-2022 | |
| Genzyme Corporation | $187.75 | 2020-2022 | |
| Lilly USA, LLC | $153.86 | 2019-2023 | Verzenio |
| Access Pro Medical, LLC | $138.46 | 2025 | Matriderm |
| Pfizer INC. | $136.06 | 2021-2023 | |
| Celgene Corporation | $118.06 | 2021-2022 | |
| Daiichi Sankyo INC. | $115.28 | 2020-2021 | |
| Incyte Corporation | $109.28 | 2020-2022 |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manasa Vulchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.